Novel Treatments Recommended for Management of Atopic Dermatitis in Adults
FRIDAY, July 25, 2025 -- In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was published online July 16 in the Journal of the American Academy of Dermatology.
Dawn M.R. Davis, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues updated previous guidelines issued by the American Academy of Dermatology on the management of atopic dermatitis in adults by providing evidence-based recommendations on use of topical and systemic therapies.
The authors developed four recommendations for atopic dermatitis management in adults, all strong, with a high certainty of evidence. Tapinarof cream is recommended for adults with moderate-to-severe atopic dermatitis. Roflumilast 0.15 percent cream is recommended for adults with mild-to-moderate atopic dermatitis. Lebrikizumab is recommended for moderate-to-severe atopic dermatitis, as is nemolizumab with concomitant topical therapy.
"Additional, long-term efficacy and safety data and data on patient-reported outcomes in real-world settings are needed to provide additional insights into the efficacy, effectiveness, and safety of these therapies for the management of atopic dermatitis," the authors write. "Comparative studies of these medications and available standard AD therapies would provide an understanding of the role of these therapies in the armamentarium of AD treatments."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Suicidal Ideation Risk Elevated for Patients With Atopic Eczema
WEDNESDAY, Sept. 17, 2025 -- Patients with atopic eczema (AE) have an increased risk for suicidal ideation (SI), according to a study presented at the European Academy of...
Lebrikizumab Efficacious, Safe for Patients With Skin of Color, Eczema
WEDNESDAY, Aug. 13, 2025 -- For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study published online July 15 in the...
High Dietary Inflammatory Index Tied to Increased Prevalence of Eczema
TUESDAY, July 15, 2025 -- A high dietary inflammatory index (DII), which quantifies the inflammatory potential of diet, is associated with increased prevalence of atopic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.